Please wait while the formulary information is being retrieved.
Drug overview for CLARISCAN (MEGLUMINE) (gadoterate meglumine):
Generic name: gadoterate meglumine
Drug class:
Therapeutic class: Diagnostic Agents
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
Generic name: gadoterate meglumine
Drug class:
Therapeutic class: Diagnostic Agents
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for CLARISCAN (MEGLUMINE) (gadoterate meglumine) have been approved by the FDA:
Indications:
Diagnostic imaging
Professional Synonyms:
Diagnostic imaging exam
Diagnostic imaging procedure
Diagnostic radiography
Diagnostic radiology
Indications:
Diagnostic imaging
Professional Synonyms:
Diagnostic imaging exam
Diagnostic imaging procedure
Diagnostic radiography
Diagnostic radiology
The following dosing information is available for CLARISCAN (MEGLUMINE) (gadoterate meglumine):
No enhanced Dosing information available for this drug.
No enhanced Administration information available for this drug.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for CLARISCAN (MEGLUMINE) (gadoterate meglumine):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for CLARISCAN (MEGLUMINE) (gadoterate meglumine):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 3 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Acute renal failure |
| Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min |
| Nephrogenic systemic fibrosis |
There are 1 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Kidney disease with likely reduction in glomerular filtration rate (GFr) |
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Asthma |
The following adverse reaction information is available for CLARISCAN (MEGLUMINE) (gadoterate meglumine):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 17 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Angioedema Urticaria |
| Rare/Very Rare |
|---|
|
Acute pancreatitis Acute renal failure Acute respiratory distress syndrome Anaphylaxis Bradycardia Bronchospastic pulmonary disease Cardiac arrhythmia Coma Cyanosis Extravasation injury Laryngismus Nephrogenic systemic fibrosis Pharyngeal edema Pulmonary edema Seizure disorder |
There are 28 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Dizziness Headache disorder Injection site sequelae Nausea Skin rash |
None. |
| Rare/Very Rare |
|---|
|
Conjunctivitis Diarrhea Drowsy Dysgeusia Eyelid edema Fatigue Fever Hypertension Malaise Pain Palpitations Paresthesia Parosmia Phlebitis after infusion Pruritus of skin Sensation of cold Sensation of warmth Sialorrhea Symptoms of anxiety Syncope Tachycardia Tremor Vomiting |
The following precautions are available for CLARISCAN (MEGLUMINE) (gadoterate meglumine):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for CLARISCAN (MEGLUMINE) (gadoterate meglumine):
WARNING: This medication may rarely cause kidney damage. The risk of kidney damage is greater if you already have kidney problems, if you are an older adult, or if you have high blood pressure or diabetes. Your doctor should check how well your kidneys are working before you receive this medication. See also Side Effects section.
WARNING: This medication may rarely cause kidney damage. The risk of kidney damage is greater if you already have kidney problems, if you are an older adult, or if you have high blood pressure or diabetes. Your doctor should check how well your kidneys are working before you receive this medication. See also Side Effects section.
The following icd codes are available for CLARISCAN (MEGLUMINE) (gadoterate meglumine)'s list of indications:
No ICD codes found for this drug.
No ICD codes found for this drug.
Formulary Reference Tool